Sean Mahase
Overview
Explore the profile of Sean Mahase including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kharouta M, Lorenz F, Mahase S, Shi H, Goyal N, Yao M
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766030
Limited metastatic squamous cell carcinoma of the oropharynx (OPC) lacks clear management guidelines, especially for HPV-associated disease. The objective of this study was to investigate if primary site radiotherapy (RT)...
2.
Miccio J, Potter N, Showkat A, Yao M, Mahase S, Ferenci M, et al.
Front Oncol
. 2024 Jun;
14:1401703.
PMID: 38919525
Introduction: MRI-guided radiotherapy (MRgRT) allows for direct motion management and real-time radiation treatment plan adaptation. We report our institutional experience using low strength 0.35T MRgRT for thoracic malignancies, and evaluate...
3.
Mahase S, Nagar H
Eur Urol Open Sci
. 2022 Sep;
44:52-53.
PMID: 36093321
[This corrects the article DOI: 10.1016/j.euros.2020.10.001.].
4.
Mahase S, Nagar H
Eur Urol Open Sci
. 2021 Aug;
22:9-16.
PMID: 34337473
Context: Radiotherapy (RT) is a valid adjuvant treatment for men with high-risk pathological features after radical prostatectomy and a salvage treatment for biochemical recurrence. A major inconvenience is that RT...
5.
Mahase S, Christos P, Wang X, Potters L, Wernicke A, Parashar B
Cureus
. 2019 Jan;
10(11):e3575.
PMID: 30656079
Purpose This study evaluates regional poverty level-dependent differences in lung cancer (LC) survival, focusing on patients receiving radiation therapy (RT). Methods and materials The Surveillance, Epidemiology, and End Results (SEER)...
6.
Dutta D, Zameer A, Mariani J, Zhang J, Asp L, Huynh J, et al.
Development
. 2018 Jul;
145(13).
PMID: 30006479
No abstract available.
7.
Mahase S, Rattenni R, Wesseling P, Leenders W, Baldotto C, Jain R, et al.
Am J Pathol
. 2017 Mar;
187(5):940-953.
PMID: 28284719
Glioblastomas (GBMs) are malignant tumors characterized by their vascularity and invasive capabilities. Antiangiogenic therapy (AAT) is a treatment option that targets GBM-associated vasculature to mitigate the growth of GBMs. However,...
8.
Dutta D, Zameer A, Mariani J, Zhang J, Asp L, Huynh J, et al.
Development
. 2014 Jun;
141(12):2414-28.
PMID: 24917498
In the embryonic CNS, development of myelin-forming oligodendrocytes is limited by bone morphogenetic proteins, which constitute one arm of the transforming growth factor-β (Tgfβ) family and signal canonically via Smads...
9.
Argaw A, Asp L, Zhang J, Navrazhina K, Pham T, Mariani J, et al.
J Clin Invest
. 2012 Jun;
122(7):2454-68.
PMID: 22653056
In inflammatory CNS conditions such as multiple sclerosis (MS), current options to treat clinical relapse are limited, and more selective agents are needed. Disruption of the blood-brain barrier (BBB) is...
10.
Zhang J, Kramer E, Mahase S, Dutta D, Bonnamain V, Argaw A, et al.
Mt Sinai J Med
. 2011 Mar;
78(2):244-57.
PMID: 21425268
Multiple sclerosis is an inflammatory demyelinating disease of the brain and spinal cord with a presumed autoimmune etiology. Conduction block in demyelinated axons underlies early neurological symptoms, whereas axonal transection...